Tag Archives: Biophytis

Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – April 22, 2025) – Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 …

Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – April 9, 2025) –  Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as …

96% of patients with obesity report experiencing muscle strength impairment, affecting their mobilityNew preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – March 24, 2025) – Biophytis SA (FP: ALBPS) (“Biophytis” or the “Company”), …

Publication of SARA-INT Phase II results for BIO101 Confirmation of Phase 3 readiness Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – March 17, 2025) – Biophytis SA (FP: ALBPS) (“Biophytis” or the “company”), a clinical-stage biotechnology company specialized in developing therapies for age-related diseases, is excited to announce a world premiere: …

Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – February 25, 2025) – Biophytis SA (FP: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company  specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking …

Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – February 11, 2025) – Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in …

Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – January 27, 2025) – Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris. …